---
tags:
  - CAD
aliases:
  - INOCA
---
- Patients with angina with evidence of myocardial ischemia from non-invasive testing (e.g. [[Positron Emission Tomography (PET)|PET]] and other [[Cardiac Stress Testing|stress test modalities]]), but have <u>no</u> flow-limiting/obstructive [[Coronary Artery Disease (CAD)|coronary artery disease]]. [^asia]
	- ![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240817145333562.webp|512]]
- Endotypes:
	- [[Vasospastic Angina]]
	- [[Microvascular Dysfunction]]
	- TODO

<center>Endotypes of INOCA</center>

| Endotype                             | Features                                                                                                                                                                                                                                                                                  | Diagnosis                                                                                                                                                                                                        |
| ------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| [[Microvascular Dysfunction]]        | Structural and/or functional abnormalities in the microvascular system<br>A limitation in the vasodilatory ability and absolute conductance ability of the microvascular system  <br>Associated with risk factors of cardiovascular disease, ventricular hypertrophy, or cardiomyopathies | Based on invasive physiologic assessment:<br>- FFR >0.80 or NHPR >0.89<br>- CFR < 2.0-2.5<br>- IMR >25U or HMR >2.5 mm Hg/cm/s                                                                                   |
| Epicardial [[Vasospastic Angina]]    | Hyper-reactive response of the epicardial coronary artery segment to vasoconstrictive stimuli                                                                                                                                                                                             | Based on provocation test using ergonovine or [[Acetylcholine\|acetylcholine]]:<br>- Ischemic Sx during test<br>- Transient total/subtotal coronary artery occlusion<br>- Ischemic ECG ‚àÜ in ‚â• 2 contiguous leads |
| Microvascular [[Vasospastic Angina]] | Spasm of vascular smooth muscle cells in prearteriolar vessels and arterioles                                                                                                                                                                                                             | Based on provocation test using [[Acetylcholine\|acetylcholine]]:<br>- Ischemic Sx during test<br>- Absence of total/subtotal coronary artery occlusion<br>- Ischemic ECG ‚àÜ in ‚â• 2 contiguous leads              |
| Masked diffuse disease               | Coronary angiography can underestimate diffuse coronary atherosclerosis.  <br>Invasive physiologic assessment and/or intravascular coronary imaging can reveal hidden coronary atherosclerosis.                                                                                           | Based on invasive physiologic assessment:<br>- FFR ‚â§0.80 or NHPR ‚â§0.89 with gradual step-up during pull back tracing<br>Based on intravascular imaging studies                                                   |

CFR = coronary flow reserve; ECG = electrocardiogram; FFR = fractional flow reserve; HMR = hyperemic microvascular resistance; IMR = index of microcirculatory resistance; INOCA = ischemia with nonobstructive coronary artery disease; NHPR = nonhyperemic pressure ratio.

![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240925173235501.webp]]
Source: Figure 2 of [^eapci]

![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240925182931940.webp]]
Figure source: Figure 1 of [^cmd-natrev]

- Sequence of evaluation:
	- Step 1: Exclude flow-limiting/obstructive <u>epicardial</u> [[Coronary Artery Disease (CAD)|CAD]]
	- Step 2: [[Ischemia with Nonobstructive Coronary Arteries (INOCA)#Physiologic Testing|Physiologic testing]] to assess for [[Microvascular Dysfunction|coronary microvascular disease]]
	- Step 3: [[Ischemia with Nonobstructive Coronary Arteries (INOCA)#Provocative Testing|Provocative testing]] to assess for <u>epicardial</u> and/or <u>microvascular</u> [[Vasospastic Angina|vasospastic angina]]
	- ![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240817153141814.webp|722]]

# Chest Pain

![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240923130154796.webp|644]]
Figure source: Figure 14 of [^cp]

# Physiologic Testing

- Comprehensive <u>physiologic</u> assessment using a pressure sensor guidewire is needed to discriminate myocardial ischemia caused by epicardial coronary artery lesions and **coronary microvascular disease** [^asia]
	- Physiologic testing cannot provide information on [[Vasospastic Angina|vasospastic angina]] [^asia]
- Metrics
	- [[Fractional Flow Reserve (FFR)]] or non-hyperemic pressure ratio (NHPR) is a standard invasive method to define ischemia-causing epicardial coronary artery lesions.[^asia]
		- FFR ‚â§0.80 and NHPR ‚â§0.89 indicate flow-limiting or ischemia-causing epicardial coronary artery stenosis
	- Index of Microvascular Resistance (IMR)

| Physiologic Index | Definition                                                                                  | Cutoff Value    | Features                                                                                                                                                           |
| ----------------- | ------------------------------------------------------------------------------------------- | --------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| FFR               | Ratio of distal coronary pressure to aortic pressure during hyperemia                       | ‚â§0.80           | Reflecting disease burden of epicardial coronary artery                                                                                                            |
| NHPR              | Ratio of distal coronary pressure to aortic pressure during the resting state               | ‚â§0.89           | Reflecting disease burden of epicardial coronary artery  <br>Several NHPRs: instantaneous wave-free ratio, resting full cycle ratio, and diastolic pressure ratio. |
| CFR               | Ratio of hyperemic coronary flow and resting coronary flow                                  | <2.0-2.5        | Reflecting both epicardial coronary artery disease and microvascular dysfunction                                                                                   |
| IMR               | Distal coronary artery pressure multiplied by hyperemic mean transit time                   | >25 U           | Microvascular-specific index                                                                                                                                       |
| HMR               | Ratio of maximal coronary flow velocity to distal coronary artery pressure during hyperemia | >2.5 mm Hg/cm/s | Microvascular-specific index                                                                                                                                       |

![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240817151502284.webp]]
Caption: Invasive physiologic indexes are helpful in identifying the presence of myocardial ischemia and discriminating the mechanisms of myocardial ischemia. Fractional flow reserve (FFR) or nonhyperemic pressure ratio (NHPR) reflects the degree of flow limitation caused by epicardial coronary artery lesions, and the index of microcirculatory resistance (IMR) or hyperemic microvascular resistance (HMR) represents the status of the microcirculatory system. Coronary flow reserve (CFR) is influenced by both macrovascular and microvascular disease status.[^asia]

# Provocative Testing

- üìù A patient can have **BOTH**, i.e. concomitant <u>epicardial</u> and <u>microvascular</u> [[Vasospastic Angina|vasospastic angina]]
	- coexistence confirmed in cases with microvascular vasospasm occurring with a lower dose of [[Acetylcholine|acetylcholine]] than epicardial artery spasm
- <u>Microvascular</u> [[Vasospastic Angina|vasospastic angina]] can be diagnosed with [[Acetylcholine|acetylcholine]] infusion during coronary angiography using a lower dose of acetylcholine compared with that of <u>epicardial</u> [[Vasospastic Angina|coronary spasm]].
- When angina and ischemic electrocardiographic changes (ST-segment depression or elevation ‚â•0.1 mV) in at least 2 contiguous leads occur after [[Acetylcholine|acetylcholine]] infusion without significant epicardial coronary artery constriction (<90%), the presence of <u>microvascular</u> [[Vasospastic Angina|spasm]] can be diagnosed
- Complications include refractory spasm by provocation test or fatal arrhythmia

# Management

![[Ischemia with Nonobstructive Coronary Arteries (INOCA)-20240925173415704.webp|627]]
Source: Figure 5 of [^eapci]

- Lifestyle modification
- Risk factor management, including [[Hypertension|hypertension]], [[Hyperlipidemia|HLD]], [[Smoking Cessation|smoking]], and [[Diabetes|diabetes]]
	- Optimal BP üíä depends on INOCA endotype
- [[Anti-Anginal Therapy]]
	- [[Calcium Channel Blockers (CCBs)]] should be considered 1st-line in patients with evidence of either epicardial or microvascular spasm following acetylcholine testing

## Management of Microvascular Angina

Table source: Table 3 of [^eapci]

| Treatment                                                                    | Mechanism of effect                                                                                                                                |
| ---------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------- |
| [[Beta-blockers\|BBs]] (Nebivolol 2.5‚Äì10 mg daily)                           | - ‚Üì Myocardial oxygen consumption<br>- Antioxidant properties                                                                                      |
| [[Calcium Channel Blockers (CCBs)\|CCBs]] (Amlodipine 10 mg daily)           | - Vascular smooth muscle relaxation<br>- ‚Üì Myocardial oxygen consumption                                                                           |
| [[Ranolazine]] (375‚Äì750 mg twice daily or 500 mg‚Äì1 g twice daily in the USA) | - Improves microvascular perfusion reserve index in patients with MVA and reduced [[Myocardial Blood Flow (MBF)#Coronary Flow Reserve (CFR)\|CFR]] |
| Trimetazidine (35 mg twice daily)                                            | - Increases cell tolerance to ischaemia by maintaining cellular homeostasis                                                                        |
| ACE inhibitors (Ramipril 2.5 - 10mg), ARBs                                   | - Improve [[Myocardial Blood Flow (MBF)#Coronary Flow Reserve (CFR)\|CFR]]<br>- ‚Üì Workload<br>- May improve small vessel remodelling               |

## Management of [[Vasospastic Angina]]

See [[Vasospastic Angina#Management|Management of Vasospastic Angina]]



[^asia]: Hwang, D., Park, S.-H., & Koo, B.-K. (2023). Ischemia With Nonobstructive Coronary¬†Artery Disease. JACC: Asia, 3(2), 169‚Äì184. https://doi.org/10.1016/j.jacasi.2023.01.004
[^cp]: Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of the American College of Cardiology. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053
[^eapci]: Kunadian, V., Chieffo, A., Camici, P. G., Berry, C., Escaned, J., Maas, A. H. E. M., Prescott, E., Karam, N., Appelman, Y., Fraccaro, C., Louise Buchanan, G., Manzo-Silberman, S., Al-Lamee, R., Regar, E., Lansky, A., Abbott, J. D., Badimon, L., Duncker, D. J., Mehran, R., ‚Ä¶ Baumbach, A. (2020). An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology &amp; Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal, 41(37), 3504‚Äì3520. https://doi.org/10.1093/eurheartj/ehaa503
[^cmd-natrev]: Camici, P. G., d‚ÄôAmati, G., & Rimoldi, O. (2014). Coronary microvascular dysfunction: mechanisms and functional assessment. Nature Reviews Cardiology, 12(1), 48‚Äì62. https://doi.org/10.1038/nrcardio.2014.160
